allos therapeutics

Brean Murray Carret & Company has lowered the price target on Allos Therapeutics (NASDAQ: ALTH) from $9 to $6 and maintains its Buy rating.

BMC reiterated its Buy rating on Allos Therapeutics (NASDAQ: ALTH). At the same time, BMC left its rating unchanged at $6 after the company's new drug, Istodax, was given a PTCL approval. On Thursday, Allos added 8.65% to its value to close the day at $2.01.

In a report released yesterday, J.P. Morgan commented on Allos Therapeutics (NASDAQ: ALTH). In the report, J.P. Morgan was very positive on the company. J.P. Morgan writes, “Allos' 1Q results had a number of moving parts, some were positive and some were negative. On the positive side, Allos...

According to Citi, Allos Therapeutics (NASDAQ: ALTH) price target is reduced to $5. Citi said that it is reducing the PT to $5 based on the lower FY2011 FOLOTYN sales guidance of $48M - $55M comparing to previous CIRA and cons estimates of $57M and $63M. “Our new growth estimates are more modest,...

JP Morgan has lowered the price target on Allos Therapeutics (NASDAQ: ALTH) from $10 to $8 and maintains its Overweight rating.

Citigroup has lowered the price target on Allos Therapeutics (NASDAQ: ALTH) from $7 to $5 and maintains its Buy rating.

J.P. Morgan is reiterating is Overweight rating on shares of Allos Therapeutics, Inc. (NASDAQ: ALTH). “We continue to like ALTH shares on reasonable expectations for Folotyn in PTCL and CTCL that have meaningful upside potential from the EU or longer term in the US,” J.P. Morgan writes. “We remain...

Citi has published a research report commenting on the 4Q results for Allos Therapeutics (NASDAQ: ALTH). In the report, Citigroup writes "ALTH confirmed today 4Q net factory sales of $11.7M (preannounced in January). 4Q EPS came in at ($0.17), vs. CIRA and Street estimates of ($0.21) and ($0.18),...

JP Morgan has published a research report for Allos Therapeutics (NASDAQ: ALTH) saying that the company is being encouraged with its clinical activity of Folotyn. In the report, JP Morgan writes "After presentation of the phase 2b non-small cell lung cancer (NSCLC) data of Folotyn versus Tarceva at...

Brean Murray Carret & Co. has initiated coverage for the following companies: Allos Therapeutics (NASDAQ: ALTH) Buy, $9 price target CNinsure (NASDAQ: CISG) Buy, $34 price target